Mills MN, Naz A, Thawani C, et al. - This study was conducted to gain insight into the safety as well as efficacy of concurrent capecitabine and stereotactic radiotherapy in the setting of breast cancer brain metastases (BCBM). This analysis involved 23 patients suffering from BCBM who received 31 stereotactic sessions to 90 lesions from 2005 to 2019 with receipt of capecitabine. A median follow-up, from stereotactic radiation, of 9.2 months was conducted. Of the 31 stereotactic sessions, 71% happened within 1 month of capecitabine. Experts noted no elevated toxicity in their series with no cases of radionecrosis. The 1-year overall survival, local control (LC), and distant intracranial control were estimated to be 46, 88, and 30%, respectively. These findings in a single institution demonstrate the safety of stereotactic radiation and capecitabine for treating BCBM cases with adequate LC.